Evidence map›Paper›PMID 35015215›Full record

ArticleNeurology and therapy2022

Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson's Disease: Real-World Evidence From G7 Countries.

Angelo Antonini, Rajesh Pahwa, Per Odin, Tove Henriksen, Michael J Soileau, Ramon Rodriguez-Cruz, Stuart H Isaacson, Aristide Merola, Susanna Lindvall, Josefa Domingos and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Does genetic testing remain relevant in advanced Parkinson's disease?Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Angelo AntoniniParkinson and Movement Disorders Unit, Study Centre for Neurodegeneration, Department of Neuroscience, University of Padova, Padova, Italy.ORCID https://orcid.org/0000-0003-1040-2807
Rajesh PahwaMedical Center, University of Kansas, Kansas, KS, USA.ORCID https://orcid.org/0000-0003-3176-6466
Per OdinUniversity of Lund, Lund, Sweden.ORCID https://orcid.org/0000-0002-0756-7478
Tove HenriksenMovement Disorder Clinic, University Hospital of Bispebjerg, Copenhagen, Denmark.
Michael J SoileauTexas Movement Disorder Specialists, Georgetown, TX, USA.
Ramon Rodriguez-CruzSynaptic Precision, Inc, Orlando, FL, USA.
Stuart H IsaacsonParkinson's Disease and Movement Disorders Center, Boca Raton, FL, USA.ORCID https://orcid.org/0000-0002-9914-5706
Aristide MerolaMadden Center for Parkinson Disease and Other Movement Disorders, Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.ORCID https://orcid.org/0000-0002-5587-726X
Susanna LindvallEuropean Parkinson's Disease Association, Sevenoaks, UK.
Josefa DomingosEuropean Parkinson's Disease Association, Sevenoaks, UK.ORCID https://orcid.org/0000-0001-9390-6183
Ali AlobaidiAbbVie Inc., North Chicago, IL, USA.ORCID https://orcid.org/0000-0002-0720-7894
Yash J JalundhwalaAbbVie Inc., North Chicago, IL, USA.
Prasanna L KandukuriAbbVie Inc., North Chicago, IL, USA.
Juan Carlos ParraAbbVie Inc., North Chicago, IL, USA.ORCID https://orcid.org/0000-0002-5613-6121
Pavnit K KukrejaAbbVie Inc., North Chicago, IL, USA.
Koray OnukAbbVie Inc., North Chicago, IL, USA.
Lars BergmannAbbVie Inc., North Chicago, IL, USA.
James PikeAdelphi Real World, Adelphi Mill, Bollington, UK.ORCID https://orcid.org/0000-0002-4208-2871
K Ray ChaudhuriKing's College and Parkinson Foundation Centre of Excellence, Kings College Hospital London, London, UK. ray.chaudhuri@kcl.ac.uk.ORCID https://orcid.org/0000-0003-2815-0505

Funding

KL2 Training ProgramKL2TR001426 · NCATS · UNIVERSITY OF CINCINNATI · PI ZELLER, MARGARET H · 2015 to 2024
$6.8M
NCATS NIH HHS KL2 TR001426
6 · The paper itself

Abstract

introductionStandardized and validated criteria to define advanced Parkinson's disease (PD) or identify patient eligibility for device-aided therapy are needed. This study assessed the psychometric properties of clinical indicators of advanced PD and eligibility for device-aided therapy in a large population.

methodsThis retrospective analysis of the Adelphi Parkinson's Disease Specific Programme collected data from device-aided therapy-naïve people with PD in G7 countries. We assessed the presence of 15 clinical indicators of advancing PD and seven indicators of eligibility for device-aided therapy in patients classified with advanced PD or as eligible for device-aided therapy by the treating physician. Accuracy was assessed using area under the curve (AUC) and multivariable logistic regression models. Construct validity was examined via known-group comparisons of disease severity and burden among patients with and without each clinical indicator.

resultsOf 4714 PD patients, 14.9% were classified with advanced PD and 17.5% as eligible for device-aided therapy by physician judgment. The presence of each clinical indicator was 1.9- to 7.3-fold more likely in patients classified with advanced PD. Similarly, the presence of device-aided therapy eligibility indicators was 1.8- to 5.5-fold more likely in patients considered eligible for device-aided therapy. All indicators demonstrated high clinical screening accuracy for identifying advanced PD (AUC range 0.84-0.89) and patients eligible for device-aided therapy (AUC range 0.73-0.80). The Unified Parkinson's Disease Rating Scale (UPDRS) score, cognitive function, quality of life, and caregiver burden were significantly worse in indicator-positive patients.

conclusionSpecific clinical indicators of advanced PD and eligibility for device-aided therapy demonstrated excellent psychometric properties in a large sample, and thus may provide an objective and reliable approach for patient identification and treatment optimization.

Indexed as

AccuracyAdvanced Parkinson’s diseaseClinical indicatorsDevice-aided therapy eligibilityValidity

Identifiers

PMID35015215
PMCPMC8857339

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.